Delivery Order SPE2DB25D3020-SPE2DB25FWKMJ
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency on August 14, 2025, for Ingrezza 40 mg capsules (30-count). This competitively awarded, firm fixed-price delivery order has a ceiling value of $3,676.12 and is scheduled for completion by September 5, 2025. The contract utilizes no set-aside designation and represents a child award under AmerisourceBergen's substantial...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a delivery order award on September 2, 2025, for the supply of Ingrezza 40 mg capsules (30-count units) valued at $14,704.48. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of September 23, 2025. The contract is funded through the Medical Supply Chain, a Defense-oriented federal agency responsible for...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Ingrezza 80 mg capsules (30-count units) under a firm fixed-price contract valued at $4,027.70. The delivery order is scheduled for completion by October 1, 2025, and will be fulfilled from the company's facility in Conshohocken, Pennsylvania. This award represents a non-competitive delivery order placed against AmerisourceBergen's existing Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $4,049.61 delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Ingrezza 60 mg capsules (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 23, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $3,676.12 delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Ingrezza 40 mg capsules (30-count units). The contract, which is not set-aside, carries a firm fixed price structure with an ultimate completion date of August 21, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location. This award represents a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $3,676.12 to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Ingrezza 40 mg capsules (30-unit quantity). This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 12, 2025, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. The contract contains no set-aside designation, reflecting AmerisourceBergen's demonstrated capability to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Ingrezza 80 mg capsules (30-count units) under a firm fixed-price contract with a ceiling value of $4,027.70. This non-set-aside delivery order is scheduled for completion by August 18, 2025, with performance conducted at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order issued against the vendor's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Ingrezza 40 mg capsules (30-count units) valued at $3.68K. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 26, 2025, with performance at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The award carries no set-aside designation, reflecting open competition among qualified vendors. This...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,119.55 firm fixed-price delivery order is for the supply of Ingrezza 40 mg capsules with a completion date of June 16, 2023. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of the medication Ingrezza 80 mg capsules. The contract has a ceiling value of $3,893.15 and a period of performance through June 6, 2024. It is a firm-fixed-price contract, with no set-aside designation, indicating open competition. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- SPE2DB25D3020Indefinite Delivery Contract
- SPE2DB25D3020-SPE2DB25FWKMJDelivery Order
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a firm fixed-price delivery order valued at $4,027.70 by the Defense Logistics Agency on September 8, 2025, for the supply of Ingrezza 80 mg capsules (30-count). This non-set-aside competitive award is scheduled for completion by September 29, 2025, and represents a single transaction under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. This prime indefinite delivery vehicle serves as a comprehensive pharmaceutical support mechanism enabling AmerisourceBergen to supply a broad range of medications, vaccines, and medical supplies to support military healthcare programs globally. The delivery order falls within AmerisourceBergen's established role as a critical vendor for federal medical procurement, particularly supporting the Defense Health Agency and other government healthcare systems. Ingrezza, a neurological treatment medication, aligns with the company's demonstrated portfolio of specialty pharmaceuticals and brand-name medications across multiple therapeutic domains. As a child contract under the larger DLA Troop Support Medical IDC, this award reflects the company's ongoing capability to meet federal pharmaceutical supply requirements through competitive procurement processes and firm fixed pricing arrangements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.0k | 9/8/25 |